We’ve recently updated our valuation analysis.

Poolbeg Pharma Valuation

Is POLB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for POLB.F?

Other financial metrics that can be useful for relative valuation.

POLB.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-7.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does POLB.F's PB Ratio compare to its peers?

The above table shows the PB ratio for POLB.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.7x
ODTC Odonate Therapeutics
SHWZ Medicine Man Technologies
HEPA Hepion Pharmaceuticals
CGTX Cognition Therapeutics
POLB.F Poolbeg Pharma

Price to Earnings Ratio vs Industry

How does POLB.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.1%
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.1%
No more companies

Price to Book Ratio vs Fair Ratio

What is POLB.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

POLB.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate POLB.F's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of POLB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies